Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

The Sheppard AFB Madrigal Youth Center and Department of the Air Force Child and Youth Programs are gearing up to host summer ...

For the co-owners of Taqueria Los Puñales, there’s a lot in the name. For starters: It’s not a restaurant, says owner David ...

Altimmune, Inc.'s pemvidutide shows promising results in MASH resolution and weight loss, paving the way for phase 3 trials.

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

BOTTOM LINE: The Atlanta Braves meet the New York Mets with a 2-1 series lead. New York has a 28-12 record in home games and a 47-34 record overall. The Mets are 33-5 in games when they out-hit their ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Former conductor of the Helena Chamber Singers Dr. Steven Michelson recently formed “Mirinesa,” a new women's choir, to have ...

Madrigal has set a list price of the Rezdiffra of $47,400 per year, ahead of any discounts or rebates, which lies within the $39,600 to $50,100 range that the influential Institute for Clinical ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Happy Pride Month! It's a great time to think about how you can put some of your hard-earned dollars toward supporting local ...